Progyny, Inc. (PGNY) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health solutions. The company operates in a single segment, serving over 590 enterprise clients with approximately 7.2 million covered lives. The business model relies on a "Smart Cycle" treatment bundle and an integrated pharmacy benefits solution (Progyny Rx).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $328.5 million | $324.0 million |
| Gross Profit | $83.1 million | $75.8 million |
| Gross Margin | 25.3% | 23.4% |
| Net Income | $24.2 million | $15.1 million |
| Diluted EPS | $0.29 | $0.17 |
| Operating Cash Flow | $45.9 million | $49.8 million |
| Cash & Marketable Securities | $225.1 million | N/A |
| Debt | $0 (Undrawn) | N/A |
Note: Cash and cash equivalents were $131.6 million and marketable securities were $93.5 million as of March 31, 2026. The company has a $200 million revolving credit facility with no amounts drawn.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1% ($4.5 million) year-over-year, driven by an increase in the number of clients and covered lives. This growth was partially offset by the non-renewal of a large client in 2025, which had an extended transition period in the first half of 2025.
- Profitability Expansion: Net income increased 61% ($9.2 million) primarily due to a 10% increase in gross profit and a significant reduction in operating expenses.
- Expense Reduction: Total operating expenses decreased 8% ($3.9 million). This was largely driven by a $12.8 million decrease in stock-based compensation expense (from $32.5 million to $19.7 million) as a major retention grant vested in late 2025.
- Capital Allocation: The company completed its $200 million share repurchase program authorized in November 2025, repurchasing 5.5 million shares for approximately $116.6 million during the quarter.
Guidance, Outlook, and Risks
- Guidance: On May 7, 2026, the company issued guidance for Q2 2026 and the full year 2026. Specific numerical targets are not detailed in this filing text but are subject to standard forward-looking statement risks.
- Outlook: Management expects to continue investing in sales and marketing to drive new client acquisition and expand offerings within the existing base. The company anticipates continued growth in the number of clients with more than 2,500 covered lives.
- Key Risks:
- Regulatory Environment: Significant exposure to evolving laws regarding reproductive rights, PBM regulations (including the Consolidated Appropriations Act of 2026), and state-level licensing requirements.
- Client Concentration: While no single client exceeded 10% of revenue in Q1 2026, the company relies heavily on the technology sector and large enterprise clients.
- Utilization Volatility: Revenue is dependent on member utilization rates, which can fluctuate based on economic conditions and treatment outcomes.
- Cybersecurity: High reliance on IT systems and third-party vendors creates risks of data breaches and operational disruptions.
Investor Verification Checklist
- Verify the specific numerical guidance for Q2 and Full Year 2026 released on May 7, 2026, which is referenced but not detailed in the text.
- Monitor the impact of the Consolidated Appropriations Act of 2026 on Progyny Rx's PBM operations and rebate pass-through requirements.
- Assess the sustainability of gross margin expansion given the one-time reduction in stock-based compensation expenses.
- Review the status of the large client non-renewal mentioned in the text to ensure no further revenue leakage occurs in subsequent quarters.
- Confirm the company's ability to maintain its "Center of Excellence" provider network amidst potential industry consolidation.